Tesaglitazar as add-on therapy to atorvastatin further improves the lipid profile in subjects with dyslipidemia

被引：0
|
作者：
Tonstad, S.
Retterstol, K.
Ose, L.
Ohman, P.
Lindberg, M.
Svensson, M.
机构：
来源：
DIABETES | 2006年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A135 / A136
页数：2
相关论文
共 50 条
  • [31] Tiotropium add-on therapy has a safety profile comparable with that of placebo in children and adolescents with symptomatic asthma
    Vogelberg, C.
    Hamelmann, E.
    Vrijlandt, E.
    Engel, M.
    El Azzi, G.
    Moroni-Zentgraf, P.
    Eickmeier, O.
    Vandewalker, M.
    ALLERGY, 2017, 72 : 414 - 415
  • [32] Dietary supplementation with bean extract improves lipid profile in overweight and obese subjects
    Birketvedt, GS
    Travis, A
    Langbakk, B
    Florholmen, JR
    NUTRITION, 2002, 18 (09) : 729 - 733
  • [33] Betahistine add-on therapy for treatment of subjects with posterior benign paroxysmal positional vertigo: a randomized controlled trial
    Sayin, Ibrahim
    Koc, Recep Haydar
    Temirbekov, Dastan
    Gunes, Selcuk
    Cirak, Musa
    Yazici, Zahide Mine
    BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY, 2022, 88 (03) : 421 - 426
  • [34] Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial
    Timmers, Silvie
    de Ligt, Marlies
    Phielix, Esther
    van de Weijer, Tineke
    Hansen, Jan
    Moonen-Kornips, Esther
    Schaart, Gert
    Kunz, Iris
    Hesselink, Matthijs K. C.
    Schrauwen-Hinderling, Vera B.
    Schrauwen, Patrick
    DIABETES CARE, 2016, 39 (12) : 2211 - 2217
  • [35] Quetiapine add-on therapy improves the depressive behaviors and hippocampal neurogenesis in fluoxetine treatment resistant depressive rats
    Wang, Ying
    Chang, Ting
    Chen, Yun-Chun
    Zhang, Rui-Guo
    Wang, Hua-Ning
    Wu, Wen-jun
    Peng, Zheng-Wu
    Tan, Qing-rong
    BEHAVIOURAL BRAIN RESEARCH, 2013, 253 : 206 - 211
  • [36] Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial
    Ray, Kausik K.
    Leiter, Lawrence A.
    Mueller-Wieland, Dirk
    Cariou, Bertrand
    Colhoun, Helen M.
    Henry, Robert R.
    Tinahones, Francisco J.
    Bujas-Bobanovic, Maja
    Domenger, Catherine
    Letierce, Alexia
    Samuel, Rita
    Del Prato, Stefano
    DIABETES OBESITY & METABOLISM, 2018, 20 (06): : 1479 - 1489
  • [37] DYNAMICS OF THE LIPID PROFILE IN POSTINFARCTION PATIENTS DURING HIGH-DOSE THERAPY WITH ATORVASTATIN
    Oleynikov, V.
    Averyanova, E.
    Barmenkova, Y.
    Golubeva, A.
    Oreshkina, A.
    ATHEROSCLEROSIS, 2022, 355 : E304 - E304
  • [38] The use of ''add-on'' treatment in HMG-COA reductase inhibitor therapy to achieve target lipid levels
    Smith, DG
    BakkerArkmema, RG
    McLain, RW
    Black, DM
    AMERICAN JOURNAL OF MANAGED CARE, 1997, 3 (10): : LC9 - LC9
  • [39] Saxagliptin improves glycaemic control either as add-on therapy to metformin or as initial combination therapy with metformin in patients with type 2 diabetes
    Gurieva, I.
    Pfuetzner, A.
    Antsiferov, M.
    Allen, E.
    Ravichandran, S.
    Chen, R.
    EUROPEAN HEART JOURNAL, 2009, 30 : 226 - 227
  • [40] Saxagliptin improves glycaemic control either as add-on therapy to metformin or as initial combination therapy with metformin in patients with type 2 diabetes
    Pfuetzner, A.
    Gurieva, I
    Antsiferov, M.
    Allen, E.
    Ravichandran, S.
    Chen, R.
    SWISS MEDICAL WEEKLY, 2009, 139 (33-34) : 168S - 169S
12345